# IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
Canonical URL: https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-2-3-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hla-a2-negative-metastatic-uveal-melanoma
Ticker: IDYA
Company: IDEAYA Biosciences
Source: IDEAYA Biosciences
Published: 2026-04-21 14:15 EST
Original Source URL: https://media.ideayabio.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-27 10:00 EST — [IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-ide892-a-potential-best-in-class-mta-cooperative-pr-d6c184c3) — Source: IDEAYA Biosciences
- 2026-07-17 13:00 EST — [IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-3e0620d8) — Source: IDEAYA Biosciences
- 2026-06-26 10:00 EST — [IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--9011f3a6) — Source: IDEAYA Biosciences
- 2026-06-17 10:00 EST — [IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-yujiro-s-hata-elected-chairman-of-its-board-of-dire-49a534d1) — Source: IDEAYA Biosciences
- 2026-06-15 10:00 EST — [IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-ide892-a-potential-best-in-class-mta-cooperative-pr-8351a4df) — Source: IDEAYA Biosciences
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)